Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece

Galafold (migalastat) - Amicus

Elfabrio (pegunigalsidase alfa-iwxj) - Protalix, Chiesi

Fabrazyme (agalsidase beta) - Sanofi

Replagal (agalsidase alfa) - Samaritan Pharma, Takeda

https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2025/program/program/paper/ispor-europe-2025/poster-session-3-2/cost-utility-analysis-of-pegunigalsidase-alfa-compared-to-agalsidase-alfa-and-agalsidase-beta-for-the-treatment-of-adult-patients-with-fabry-disease-in-greece

Katerina Vellopoulou, MSc 1; Katerina Lioliou, MSc 1; Figaleia Karathanou, MSc 1; Eirini Kiorpelidi, MSc 2; Ilias Pyrnokokis, MSc 2; Khashayar Azimpour, PhD 3; Irene Koulinska, PhD 4; Evangelia Dounousi, PhD 5; Georgios Tsivgoulis, PhD 6; Georgia Kourlaba, PhD 7.

Nov 11, 2025